Prospective Trial on Tolerability and Efficacy of Adjuvant Nedaplatin Plus Docetaxel for Non‐Small Cell Lung Cancer
Cancer Science · 2026
DOI: 10.1111/cas.70446 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Koji Teramoto und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Shiga University of Medical Science, Otsu, Shiga, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Docetaxel, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Shiga Prefecture (Japan).
Abstract (Originalsprache)
Nedaplatin is a second‐generation platinum compound with reduced nephrotoxicity compared with cisplatin. Given its favorable tolerability in advanced non‐small cell lung cancer (NSCLC), we prospectively evaluated the tolerability and efficacy of an adjuvant nedaplatin plus docetaxel chemotherapy regimen in patients with completely resected NSCLC. Patients with stage IB–IIIA NSCLC who had undergone complete surgical resection received nedaplatin (80 mg/m 2 ) and docetaxel (60 mg/m 2 ) intravenously on day 1 once every 4 weeks for up to four cycles. The primary endpoint was treatment tolerability, defined as completion of the planned four cycles, and compared with historical data for the standard cisplatin plus vinorelbine regimen. The secondary endpoint was efficacy, determined by relapse‐free survival (RFS) after surgery. Thirty‐five patients were enrolled, with median age of 65 years (range, 36–77 years). Adenocarcinoma (57.1%) and stage II disease (60.0%) were most common. Dose reductions were needed in some patients, however, 74.3% of patients ( n = 26) completed all four cycles, meeting the primary endpoint. Grade 3 or 4 neutropenia and anorexia occurred in 67.8% and 9.0% of patients, respectively. No grade 3 or 4 renal dysfunction was noted. Concerning efficacy, the median RFS time was 63 months (95% confidence interval [CI], 20–NE), and the 5‐year overall survival rate was 85.7% (95% CI, 70.0–93.9). Long‐term retrospective follow‐up (median: 119 months) showed that the 10‐year RFS rate was 52.9% (95% CI, 36.1–69.1). These results indicate that adjuvant chemotherapy with nedaplatin plus docetaxel is tolerable and effective in patients with completely resected NSCLC. Trial Registration: UMIN number: 000004634
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Shiga University of Medical Science, Otsu, Shiga, Japan.
- Center for Advanced Medicine Against Cancer, Shiga University of Medical Science, Otsu, Shiga, Japan.
- Department of Surgery, Shiga University of Medical Science, Shiga University of Medical Science, Otsu, Shiga, Japan.
- Department of Thoracic Surgery, National Hospital Organization Kyoto Medical Cencer, Kyoto, Japan.
- Department of Thoracic Surgery, Ijinkai Takeda General Hospital, Kyoto, Japan.
ORCID-Profile: Koji Teramoto, Masayuki Hashimoto
Förderung
- Shiga Prefecture (Japan)
Zitieren
APA
Teramoto, K., Kaku, R., Igarashi, T., Hashimoto, M., Kitamura, S., Motoishi, M., Suzumura, Y., Sawai, S., Daigo, Y., & Hanaoka, J. (2026). Prospective Trial on Tolerability and Efficacy of Adjuvant Nedaplatin Plus Docetaxel for Non‐Small Cell Lung Cancer. Cancer Science. https://doi.org/10.1111/cas.70446
Vancouver
Teramoto K, Kaku R, Igarashi T, Hashimoto M, Kitamura S, Motoishi M, et al. Prospective Trial on Tolerability and Efficacy of Adjuvant Nedaplatin Plus Docetaxel for Non‐Small Cell Lung Cancer. Cancer Science. 2026. doi:10.1111/cas.70446
BibTeX
@article{Teramoto2026,
author = {Teramoto, Koji and Kaku, Ryosuke and Igarashi, Tomoyuki and Hashimoto, Masayuki and Kitamura, Shoji and Motoishi, Makoto and Suzumura, Yuji and Sawai, Satoru and Daigo, Yataro and Hanaoka, Jun},
title = {Prospective Trial on Tolerability and Efficacy of Adjuvant Nedaplatin Plus Docetaxel for Non‐Small Cell Lung Cancer},
journal = {Cancer Science},
year = {2026},
doi = {10.1111/cas.70446}
}
EUVIMED